£2m investment to accelerate Forge Editing and company growth

Forge Genetics has raised £2m in equity funding from the Midlands Engine Investment Fund II, through its appointed fund manager Mercia Ventures, with support from the British Business Bank.

The investment will allow us to scale our commercial work developing engineered bacterial strains for pharmaceutical and biotechnology companies, while accelerating R&D to adapt Forge Editing for use in mammalian cells. Since launching less than two years ago, we have secured over £2m in customer contracts and built a growing team at the University of Nottingham. This funding supports the next phase of our growth as we expand capacity, strengthen our platform, and move Forge Editing into new application areas.

Forge Editing was developed to enable precise genetic changes in organisms that are difficult or impossible to engineer using existing tools such as CRISPR. By improving cell survival and allowing greater control over editing outcomes, the platform supports faster strain development and more reliable results for industrial and therapeutic applications. This funding strengthens our ability to deliver for existing customers while opening up longer-term opportunities in cell and gene therapy.